AB2 Bio to Participate in Orphan Disease Panel Discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event Investors can pre-register for the event here LAUSANNE, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- AB2 Bio Ltd., a Phase 3 clinical-stage biotech company developing innovative therapies for the...

AB2 Bio Appoints Dr Djordje Filipovic as Chief Commercial Officer Will drive commercial strategy and execution of Tadekinig alfa, currently in Phase 3Joins AB2 Bio from Novartis and has extensive commercial and strategic experience LAUSANNE, Switzerland, Dec. 16,...

AB2 Bio and WuXi Biologics Announce Collaboration to Accelerate Commercial-Scale Manufacturing of Tadekinig alfa Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH)WuXi Biologics to undertake commercial...

AB2 Bio Appoints Michael Soldan CEO LAUSANNE, Switzerland, March 03, 2020 (GLOBE NEWSWIRE) -- AB2 Bio Ltd, a Swiss advanced clinical-stage biotech company specialized in developing innovative therapies for the treatment of severe...